Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Post by Financials101on Jul 06, 2020 3:42pm

245 Views

Post# 31230327

Essential Reading on Short Selling/Manipulation

Great article about clearing houses and the origins of the fed for anybody with some downtime later.

Our Financial Oligarchy; Emperors of a Brave New World

Great article about naked short selling and the origins of the fed. Highlights trillion dollar lawsuit.

https://stocktrades.exchange/2020/07/06/our-financial-oligarchy-emperors-of-a-brave-new-world-3/

this one works better for mobile users
https://archive.vn/mIFSF

Bullboard Posts

Debt-free cannabis company set for next stage of growth

Debt-free cannabis company set for next stage of growth

BMO evolves InvestorLine with enhanced tools for options trading

BMO evolves InvestorLine with enhanced tools for options trading

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity

Visionstate set to leverage success in the U.S. market

Visionstate set to leverage success in the U.S. market